Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Office of the Chief Medical and Scientific Officer, American Cancer Society, Atlanta, Georgia.
Cancer Epidemiol Biomarkers Prev. 2021 Aug;30(8):1554-1565. doi: 10.1158/1055-9965.EPI-20-1809. Epub 2021 Jun 4.
It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer. Recommended screening options include colonoscopy, sigmoidoscopy, CT colonography, guaiac fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). Colorectal cancer screening programs can benefit from knowledge of patterns of use by test type and within population subgroups.
Using 2018 National Health Interview Survey (NHIS) data, we examined colorectal cancer screening test use for adults aged 50-75 years ( = 10,595). We also examined time trends in colorectal cancer screening test use from 2010-2018.
In 2018, an estimated 66.9% of U.S. adults aged 50-75 years had a colorectal cancer screening test within recommended time intervals. However, the prevalence was less than 50% among those aged 50-54 years, those without a usual source of health care, those with no doctor visits in the past year, and those who were uninsured. The test types most commonly used within recommended time intervals were colonoscopy within 10 years (61.1%), FOBT or FIT in the past year (8.8%), and FIT-DNA within 3 years (2.7%). After age-standardization to the 2010 census population, the percentage up-to-date with CRC screening increased from 61.2% in 2015 to 65.3% in 2018, driven by increased use of stool testing, including FIT-DNA.
These results show some progress, driven by a modest increase in stool testing. However, colorectal cancer testing remains low in many population subgroups.
These results can inform efforts to achieve population colorectal cancer screening goals.
强烈建议年龄在 50-75 岁的成年人进行结直肠癌筛查。推荐的筛查选项包括结肠镜检查、乙状结肠镜检查、CT 结肠成像、愈创木脂粪便潜血检测(FOBT)、粪便免疫化学检测(FIT),或最近推出的 FIT-DNA(FIT 与粪便 DNA 检测相结合)。结直肠癌筛查计划可以从了解不同测试类型和人群亚组内的使用模式中受益。
我们使用 2018 年全国健康访谈调查(NHIS)数据,检查了年龄在 50-75 岁的成年人(n=10595)的结直肠癌筛查测试使用情况。我们还检查了 2010-2018 年结直肠癌筛查测试使用的时间趋势。
2018 年,估计有 66.9%的美国 50-75 岁成年人在推荐的时间间隔内进行了结直肠癌筛查测试。然而,在 50-54 岁的人群中,这一比例不到 50%,在没有常规医疗来源的人群中,在过去一年没有就诊的人群中,以及没有保险的人群中,这一比例更低。在推荐的时间间隔内最常使用的测试类型是在过去 10 年内进行结肠镜检查(61.1%)、在过去一年进行 FOBT 或 FIT(8.8%),以及在过去 3 年内进行 FIT-DNA(2.7%)。在对 2010 年人口普查人口进行年龄标准化后,2015 年 CRC 筛查的比例为 61.2%,2018 年上升至 65.3%,这得益于粪便检测的使用增加,包括 FIT-DNA。
这些结果表明取得了一些进展,这得益于粪便检测的适度增加。然而,在许多人群亚组中,结直肠癌检测仍然较低。
这些结果可以为实现人群结直肠癌筛查目标提供信息。